

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Blue Cross/Blue Shield of Michigan	Research/Research Grants ‡ Michigan Anticoagulation Quality Improvement Initiative (MAQI2)	None (\$0)	Vascular Medicine
BMS	Research/Research Grants ‡ AF Shared Decision-Making	None (\$0)	Vascular Medicine
boeinger-ingelheim	Consultant Fees/Honoraria	Significant (>= \$5,000)	Vascular Medicine
Bristol-Meyers Squibb	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
Fibromuscular Disease Society of America	Research/Research Grants ‡ US FMD Registry	None (\$0)	Vascular Medicine
Janssen Pharamaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Vascular Medicine
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
Pfizer Inc	Research/Research Grants ‡ Cost of Warfarin	None (\$0)	Vascular Medicine
sanofi-aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Society for Vascular Medicine ‡ non-profit	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Vascular Medicine

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2012	anticoagulation	Defendant	care of VTE	None (\$0)
2012	anticoagulation	Defendant	Anticoagulation use	None (\$0)

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 1/3/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 1/3/2020

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 1/3/2020

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 1/3/2020

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.